Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Earnings Roundup: Eisai's Accelerated Perampanel Development Hits The Brakes; Takeda Averts Actos Setbacks For Now

This article was originally published in PharmAsia News

Executive Summary

TOKYO - A busy Friday of quarterly earnings presentations gave a first glimpse of the full impact of the March 11 earthquake and tsunami in Northern Japan. Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co., Ltd., Daiichi Sankyo Co. Ltd, Mitsubishi Tanabe Pharma Corp. and Dainippon Sumitomo Pharma Co. Ltd. all reported July 29 earnings for the first full quarter since the earthquake, but perhaps the biggest news of the day was an announcement from Eisai Co. Ltd. on a setback to what had been an ambitious drive for a key drug's approval

You may also be interested in...



Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China

The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).

Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China

The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).

Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines

TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule

Related Content

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel